PI3K p85α/p55γ (phospho-Y467/Y199) polyclonal antibody 
Datasheet
COA
MSDS
SHIP
Product Name :
PI3K p85α/p55γ (phospho-Y467/Y199) polyclonal antibody Background :
The enzyme phosphatidylinositol 3 kinase (PI3 kinase) is a lipid kinase that generates phosphatidylinositol 3, 4, 5-triphosphate in response to receptor activation in many signal transduction pathways. Class IA PI3Ks exist as a heterodimer of a catalytic 110 kDa (p110) and a regulatory p85 subunit (e.g. p85 alpha). p85 alpha is an adaptor molecule that regulates the activity of the catalytic p110 subunit by binding to phosphorylated receptor tyrosine kinases (RTKs) through its SH2 domain and mediating the interaction between p110 and the plasma membrane. p85 alpha is necessary for insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
PI3K p85α/p55γ (phospho-Y467/Y199) polyclonal antibody detects endogenous levels of PI3K p85α only when phosphorylated at Tyr467. This antibody also detects PI3K p55γ when phosphorylated at Tyr199. Immunogen :
Synthetic phosphopeptide derived from human PI3K p85α/p55γ around the phosphorylation site of Tyrosine 467/199. Conjugate :
Unconjugated Modification :
Phosphorylation
PI3K p85α/p55γ (phospho-Y467/Y199) polyclonal antibody Background :
The enzyme phosphatidylinositol 3 kinase (PI3 kinase) is a lipid kinase that generates phosphatidylinositol 3, 4, 5-triphosphate in response to receptor activation in many signal transduction pathways. Class IA PI3Ks exist as a heterodimer of a catalytic 110 kDa (p110) and a regulatory p85 subunit (e.g. p85 alpha). p85 alpha is an adaptor molecule that regulates the activity of the catalytic p110 subunit by binding to phosphorylated receptor tyrosine kinases (RTKs) through its SH2 domain and mediating the interaction between p110 and the plasma membrane. p85 alpha is necessary for insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
PI3K p85α/p55γ (phospho-Y467/Y199) polyclonal antibody detects endogenous levels of PI3K p85α only when phosphorylated at Tyr467. This antibody also detects PI3K p55γ when phosphorylated at Tyr199. Immunogen :
Synthetic phosphopeptide derived from human PI3K p85α/p55γ around the phosphorylation site of Tyrosine 467/199. Conjugate :
Unconjugated Modification :
Phosphorylation
-
Western blot (WB) analysis of PI3K p85α/p55γ (phospho-Y467/Y199) polyclonal antibody at 1:500 dilution Lane1:COS-7 whole cell lysate(40ug) Lane2:H1792 whole cell lysate(40ug) Lane3:MG63 whole cell lysate(40ug) Lane4:The Brain tissue lysate of Rat(40ug) Lane5:MEF whole cell lysate(40ug) Lane6:The Heart tissue lysate of Rat(40ug) -
Immunohistochemistry (IHC) analyzes of p-PI3K p85α (Y467)/p55γ (Y199) pAb in paraffin-embedded human breast carcinoma_x000D_ tissue.
Estrogen-Sensitive PTPRO Expression Represses Hepatocellular Carcinoma Progression
by Control of STAT3
PMCID: Pubmed No.:22821478
Paeoniflorin Attenuates Lipopolysaccharide-Induced Permeability of Endothelial Cells: Involvements of F-Actin Expression and Phosphorylations of PI3K/Akt and PKC
PMCID: Pubmed No.:23053726
Effect of Tenuifoliside A isolated from Polygala tenuifolia on the ERK and PI3K pathways in C6 glioma cells.
PMCID: Pubmed No.:24877714
Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells
PMCID: Pubmed No.:25193113
NMMHC IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3-NF-B signalling pathways in the endothelium
PMCID: Pubmed No.:25881103
Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells
PMCID: Pubmed No.:25193113
NMMHC IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3-NF-B signalling pathways in the endothelium
PMCID: Pubmed No.:25881103
Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
PMCID: Pubmed No.:28529576
Type II cyclic guanosine monophosphate-dependent protein kinase inhibits Rac1 activation in gastric cancer cells
PMCID: Pubmed No.:26171059
PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis
PMCID: Pubmed No.:25826083
VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR–PI3K–AKT pathway
PMCID: Pubmed No.:31605014
Rottlerin acts as a therapeutic in primary open-angle glaucoma by targeting the trabecular meshwork via activation of Rap1 signaling
PMCID: Pubmed No.:32360586
Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1
PMCID: Pubmed No.:32426266
Akt phosphorylation regulated by IKKε in response to low shear stress leads to endothelial inflammation via activating IRF3
PMCID: Pubmed No.:33370582
Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway
PMCID: Pubmed No.:32877753
DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways
PMCID: Pubmed No.:30569110
Antiproliferative and pro‑apoptotic effects of Cyclocarya paliurus polysaccharide and X‑ray irradiation combination on SW480 colorectal cancer cells
PMCID: Pubmed No.:31485627
Chemical Constituents and Hypoglycemic Mechanisms of Dendrobium nobile in Treatment of Type 2 Diabetic Rats by UPLC-ESI-Q-Orbitrap, Network Pharmacology and In Vivo Experimental Verification
PMCID: Pubmed No.:36985655
Oat β-D-glucan ameliorates type II diabetes through TLR4/PI3K/AKT mediated metabolic axis
PMCID: Pubmed No.:37516222
Identification of quality markers for Cyanotis arachnoidea and analysis of its physiological mechanism based on chemical pattern recognition, network pharmacology, and experimental validation
PMCID: Pubmed No.:37719108
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.
Price/Size :
USD 368/1mg/vial
Tips:
For phospho antibody, we provide phospho peptide（0.5mg) and non-phospho peptide(0.5mg).Describe :
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.Formula:
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.
Storage:
The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C.
Note :
This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.